Free Trial

LLA.L,0P0001T9GN,0 (LLA) Competitors

LLA vs. DXRX, AGL, ABDX, VRCI, YGEN, GENI, GDR, PRM, LLAI, and IDHC

Should you be buying LLA.L,0P0001T9GN,0 stock or one of its competitors? The main competitors of LLA.L,0P0001T9GN,0 include Diaceutics (DXRX), ANGLE (AGL), Abingdon Health (ABDX), Verici Dx (VRCI), Yourgene Health (YGEN), GENinCode (GENI), genedrive (GDR), Proteome Sciences (PRM), LungLife AI (LLAI), and Integrated Diagnostics (IDHC). These companies are all part of the "diagnostics & research" industry.

LLA.L,0P0001T9GN,0 vs.

LLA.L,0P0001T9GN,0 (LON:LLA) and Diaceutics (LON:DXRX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, community ranking, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.

LLA.L,0P0001T9GN,0 has a net margin of 0.00% compared to Diaceutics' net margin of -7.37%. Diaceutics' return on equity of -4.19% beat LLA.L,0P0001T9GN,0's return on equity.

Company Net Margins Return on Equity Return on Assets
LLA.L,0P0001T9GN,0N/A -48.59% -27.28%
Diaceutics -7.37%-4.19%-3.99%

Diaceutics has higher revenue and earnings than LLA.L,0P0001T9GN,0. Diaceutics is trading at a lower price-to-earnings ratio than LLA.L,0P0001T9GN,0, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LLA.L,0P0001T9GN,0N/AN/A-£4.47M-£0.12N/A
Diaceutics£23.70M4.78-£1.75M-£0.02-6,700.00

5.4% of LLA.L,0P0001T9GN,0 shares are held by institutional investors. Comparatively, 52.3% of Diaceutics shares are held by institutional investors. 34.3% of Diaceutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

LLA.L,0P0001T9GN,0 has a beta of -0.3, suggesting that its share price is 130% less volatile than the S&P 500. Comparatively, Diaceutics has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500.

Diaceutics has a consensus price target of GBX 160, indicating a potential upside of 19.40%.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LLA.L,0P0001T9GN,0
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Diaceutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Diaceutics had 3 more articles in the media than LLA.L,0P0001T9GN,0. MarketBeat recorded 3 mentions for Diaceutics and 0 mentions for LLA.L,0P0001T9GN,0. LLA.L,0P0001T9GN,0's average media sentiment score of 0.00 beat Diaceutics' score of -0.12 indicating that LLA.L,0P0001T9GN,0 is being referred to more favorably in the media.

Company Overall Sentiment
LLA.L,0P0001T9GN,0 Neutral
Diaceutics Neutral

Diaceutics received 12 more outperform votes than LLA.L,0P0001T9GN,0 when rated by MarketBeat users.

CompanyUnderperformOutperform
LLA.L,0P0001T9GN,0N/AN/A
DiaceuticsOutperform Votes
12
85.71%
Underperform Votes
2
14.29%

Summary

Diaceutics beats LLA.L,0P0001T9GN,0 on 11 of the 14 factors compared between the two stocks.

Get LLA.L,0P0001T9GN,0 News Delivered to You Automatically

Sign up to receive the latest news and ratings for LLA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

LLA vs. The Competition

MetricLLA.L,0P0001T9GN,0Diagnostics & Research IndustryMedical SectorLON Exchange
Market CapN/A£1.50B£5.70B£1.46B
Dividend YieldN/A5.44%5.00%11.39%
P/E Ratio-125.003.93139.541,664.16
Price / SalesN/A1,831.851,622.80190,038.53
Price / CashN/A10.2837.6533.89
Price / BookN/A3.114.832.88
Net Income-£4.47M£86.46M£116.15M£133.44M

LLA.L,0P0001T9GN,0 Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DXRX
Diaceutics
1.4309 of 5 stars
1.43 / 5 stars
GBX 126.50
+1.2%
GBX 160
+26.5%
+27.4%£106.84M£23.70M-6,325.00151Analyst Forecast
News Coverage
AGL
ANGLE
2.1264 of 5 stars
2.13 / 5 stars
GBX 11.25
flat
GBX 70
+522.2%
-33.8%£36.29M£2.19M-140.63650News Coverage
ABDX
Abingdon Health
0 of 5 stars
0.00 / 5 stars
GBX 9.50
-2.6%
N/A-13.2%£18.00M£5.34M-950.0084
VRCI
Verici Dx
0 of 5 stars
0.00 / 5 stars
GBX 6.87
+1.8%
N/A-24.0%£16.66M£4.33M-343.5014Gap Down
YGEN
Yourgene Health
0 of 5 stars
0.00 / 5 stars
N/AN/A+0.0%£16.43M£29.67M-51.50253
GENI
GENinCode
0 of 5 stars
0.00 / 5 stars
N/AN/A-43.3%£11.95M£2.16M-98.142,300
GDR
genedrive
0 of 5 stars
0.00 / 5 stars
GBX 2.13
+5.2%
N/A-81.4%£11.57M£49,000.00-53.2543News Coverage
Gap Down
PRM
Proteome Sciences
0 of 5 stars
0.00 / 5 stars
GBX 2.85
-18.3%
N/A-57.9%£8.41M£5.03M-285.00240News Coverage
Gap Down
High Trading Volume
LLAI
LungLife AI
0 of 5 stars
0.00 / 5 stars
GBX 13.25
flat
N/A-87.2%£4.06M£98,566.00-110.4215
IDHC
Integrated Diagnostics
0 of 5 stars
0.00 / 5 stars
GBX 0.36
+2.9%
N/A-16.0%£2.10M£4.75B12.026,692Gap Down

Related Companies and Tools


This page (LON:LLA) was last updated on 9/18/2024 by MarketBeat.com Staff
From Our Partners